Weiss Ratings Reiterates “Sell (D-)” Rating for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB)‘s stock had its “sell (d-)” rating reiterated by stock analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Several other analysts have also recently issued reports on ANAB. HC Wainwright upped their price objective on AnaptysBio from $38.00 to $59.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. JPMorgan Chase & Co. upped their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Wedbush reissued an “outperform” rating and set a $45.00 price target on shares of AnaptysBio in a research report on Tuesday, September 30th. Finally, UBS Group reissued a “neutral” rating and set a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.75.

AnaptysBio Trading Down 0.2%

NASDAQ ANAB opened at $31.77 on Wednesday. The stock’s 50 day moving average is $22.85 and its 200 day moving average is $22.21. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $36.54. The stock has a market cap of $889.46 million, a PE ratio of -7.09 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.16. The business had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. On average, analysts forecast that AnaptysBio will post -6.08 EPS for the current fiscal year.

Institutional Trading of AnaptysBio

Several institutional investors have recently bought and sold shares of ANAB. First Light Asset Management LLC grew its holdings in AnaptysBio by 433.3% in the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after purchasing an additional 3,764,720 shares during the period. Assenagon Asset Management S.A. grew its holdings in AnaptysBio by 4,852.7% in the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after purchasing an additional 822,975 shares during the period. Caption Management LLC grew its holdings in AnaptysBio by 106.3% in the first quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company’s stock valued at $435,000 after purchasing an additional 394,634 shares during the period. Woodline Partners LP grew its holdings in AnaptysBio by 63.1% in the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after purchasing an additional 305,950 shares during the period. Finally, 683 Capital Management LLC grew its holdings in AnaptysBio by 155.6% in the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after purchasing an additional 304,373 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.